Skip to Main Content

Browse issues

Volume 52, Issue 9, September 2022

Review Article

Satoshi Kobayashi and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 959–965, https://doi.org/10.1093/jjco/hyac101

Some standard treatments for non-elderly patients with advanced pancreatic cancer could be applied for the elderly, but further studies are warranted to elucidate the indication criteria for each regimen using geriatric assessment.

Tomotaka Suzuki and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 966–974, https://doi.org/10.1093/jjco/hyac111

Original Article

Dermatology

I-Chieh Chuang and Chiau-Sheng Jang
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 975–981, https://doi.org/10.1093/jjco/hyac093

For Stage III/IV, non-BRAF acral lentiginous melanoma, microscopic evaluation of lymphovascular invasion, ulceration and tumor-infiltrating lymphocytes along with CD8/CD4 and PD-L1 immunoprofiles, may help predict patient survival.

Gastrointestinal Surgery

Keiichiro Nakajo and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 982–991, https://doi.org/10.1093/jjco/hyac090

Salvage endoscopic submucosal dissection is the effective treatment for local recurrence after chemoradiotherapy for esophageal cancer compared with salvage endoscopic resection.

Gynecology

Po-Chien Shen and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 992–1000, https://doi.org/10.1093/jjco/hyac077

A 5-CpG signature risk model was established with high AUC for the 5-year OS. Gene mutations were more likely in the low-risk group with favourable outcome.

Ryutaro Yamada and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1001–1007, https://doi.org/10.1093/jjco/hyac087

We first reported the prevalence of sarcopenia stringently confirmed in accordance with the current international standard in patients with gynecological cancer.

Head & Neck

Jie Wang and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1008–1013, https://doi.org/10.1093/jjco/hyac094

Our study evaluated the prognostic value of S-100 protein and Ki-67 labeling index in 85 patients with olfactory neuroblastomas, and our results suggested that they were reliable prognostic factors.

Hematology

Makoto Yoshimitsu and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1014–1020, https://doi.org/10.1093/jjco/hyac086

A phase I study demonstrated tolerability and safety of HBI-8000 in Japanese patients with non-Hodgkin’s lymphoma. The maximum tolerated dose is 40 mg BIW. Preliminary efficacy results are encouraging.

Orthopedics/Sarcoma

Hiroshi Urakawa and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1021–1028, https://doi.org/10.1093/jjco/hyac071

Though JCOG1610 gave only descriptive results, the superiority of preoperative denosumab was not observed in patients with giant cell tumor of bone without possible post-operative large bone defect in terms of relapse-free survival.

Ryunosuke Oyama and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1029–1038, https://doi.org/10.1093/jjco/hyac078

TXA administration safely and effectively reduces blood loss in patients undergoing surgery for BSTT with no increase in the rate of adverse events.

Palliative and Supportive Care

Takahiro Higashibata and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1039–1044, https://doi.org/10.1093/jjco/hyac085

The effect of a home-based nursing service during chemotherapy on the place of care at the end of life is unknown. This retrospective study showed that it was significantly associated with the transfer to home care immediately after the last chemotherapy treatment.

Thoracic Surgery

Hao Yang and Tonghua Mei
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1045–1055, https://doi.org/10.1093/jjco/hyac062

Visceral pleural invasion is a useful and valid predictor in small-cell lung cancer, especially in patients with N0 disease. Clinicians should pay more attention to these patients.

Urology

Yoichiro Tohi and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1056–1061, https://doi.org/10.1093/jjco/hyac092

Criteria adherence was not associated with unfavorable pathology with regard to radical prostatectomy in patients who opt for active surveillance.

Short communication

Wataru Nakata and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1062–1066, https://doi.org/10.1093/jjco/hyac089

We developed an artificial intelligence-based deep learning algorithm for prediction of time to castration-resistant prostate cancer of >24 months or not in metastatic hormone-naïve prostate cancer.

Image of the Month

Dongping Zhang and others
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1067–1068, https://doi.org/10.1093/jjco/hyac084

Cancer Statistics Digest

Kayo Nakata and Kumiko Saika
Japanese Journal of Clinical Oncology, Volume 52, Issue 9, September 2022, Pages 1069–1071, https://doi.org/10.1093/jjco/hyac136
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close